Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer

Maximilian Kießler,1 Ioana Plesca,1 Ulrich Sommer,2 Rebekka Wehner,1,3,4 Friederike Wilczkowski,1 Luise Müller,1 Antje Tunger,1,3 Xixi Lai,1 Anke Rentsch,5 Kenneth Peuker,6,7 Sebastian Zeissig,6,7,8 Adrian M Seifert ©,3,8 Lena Seifert,3,8 Jürgen Weitz,3,4,8 Michael Bachmann,3,4,5,7,9 Martin Bornhäuser,3,4,5,6,7 Daniela Aust,2,3,4,10 Gustavo Baretton,2,3,4,10 Marc Schmitz ©,1,3,4,7

ABSTRACT

Background Plasmacytoid dendritic cells (pDCs) play a key role in the induction and maintenance of antitumor immunity. Conversely, they can act as tolerogenic DCs by inhibiting tumor-directed immune responses. Therefore, pDCs may profoundly influence tumor progression. To gain novel insights into the role of pDCs in colon cancer, we investigated the frequency and clinical relevance of pDCs in primary tumor tissues from patients with colon cancer with different clinicopathological characteristics.

Methods Immunohistochemical stainings were performed to explore the frequency of tumor-infiltrating BDCA-2+ pDCs in patients with colon cancer. Statistical analyses were conducted to determine an association between the pDC density and clinicopathological characteristics of the patients. Furthermore, we used multiplex immunofluorescence stainings to evaluate the localization and phenotype of pDCs in stroma and tertiary lymphoid structures (TLS) of colon cancer tissues.

Results An increased density of infiltrating pDCs was associated with lower Union for International Cancer Control (UICC) stages. Furthermore, a higher pDC frequency was significantly correlated with increased progression-free and overall survival of patients with colon cancer. Moreover, a lower number of colon cancer-infiltrating pDCs was significantly and independently linked to worse prognosis. In addition, we found that a proportion of pDCs shows a nuclear expression of the transcription factor interferon regulatory factor 7 (IRF7), which is characteristic for an activated phenotype. In various tumor stroma regions, IRF7+ pDCs were located in the neighborhood of granzyme B-expressing CD8+ T cells. Moreover, pDCs were identified as a novel component of the T cell zone of colon cancer-associated TLS, which are major regulators of adaptive antitumor immunity. A proportion of TLS-associated pDCs displayed a nuclear IRF7 expression and was preferentially located close to CD4+ T cells.

Conclusions These results indicate that higher densities of tumor-infiltrating pDCs are associated with prolonged survival of patients with colon cancer. Moreover, colon cancer-infiltrating pDCs may represent a novel prognostic factor. The colocalization of activated pDCs and T cells in tumor stroma and within TLS may contribute to the correlation between higher pDC densities and better prognosis. In addition, our findings may have implications for the design of novel immunotherapeutic strategies that are based on targeting colon cancer-infiltrating pDCs.

BACKGROUND

Accumulating evidence indicates that the tumor immune contexture comprising the spatial organization, density, and functional orientation of tumor-infiltrating immune cells plays a critical role for the clinical outcome of patients with cancer.1–4 Thus, it has been reported that higher frequencies of CD45RO+ T helper (Th) 1 cells and CD8+ T cells are associated with prolonged survival of patients with cancer.1,3 In addition, recent studies provided evidence that higher densities of tumor-infiltrating CD8+ T cells at baseline correlate with an improved clinical efficacy of immune checkpoint inhibitor (CPI) therapy, which evolved as a very promising treatment modality for patients with cancer.5,6

Dendritic cells (DCs) play a key role in the orchestration of innate and adaptive antitumor immunity. Consequently, DCs may profoundly influence tumor progression and may have a significant impact on the clinical outcome of patients with cancer. When investigating the clinical impact of native human blood DC subsets, it has been demonstrated that a higher expression of specific gene signatures for myeloid DC1 and DC2 is associated with a higher probability for disease-free survival of patients with luminal breast cancer.7 Furthermore, a higher DC1-specific gene signature was significantly linked to improved survival in patients with cutaneous melanoma, breast invasive carcinoma, head and neck squamous cell carcinoma, and lung adenocarcinoma.8

Plasmacytoid DCs (pDCs) represent another major subset of human...
blood-circulating DCs that are characterized by their selective phenotype (BDCA-2⁺, BDCA-4⁺, CD123⁺, CD1c⁺, CD11c⁺, CD14⁺, CD141⁺) and by their extraordinary capacity to produce large amounts of type I interferon (IFN) upon stimulation.⁹ ¹⁰ Functional studies revealed that activated pDCs efficiently enhance the antitumoral properties of natural killer and T cells.¹¹ ¹² Moreover, it has been reported that pDCs kill tumor cells directly via tumor necrosis factor-related apoptosis-inducing ligand and granzyme B (GrzB)-dependent mechanisms.¹³ ¹⁴ Based on these functional properties, stimulated pDCs can efficiently exhibit antitumor responses in vivo. Thus, intratumoral pDC administration led to tumor regression in a B16 melanoma mouse model.¹⁵ In addition, it has been shown in an orthotopic murine mammary tumor model that the intratumoral application of a toll-like receptor 7 (TLR7) ligand results in the activation of tumor-associated pDCs and tumor regression.¹⁰ In a clinical trial, intranodal injections of activated pDCs loaded with tumor antigen-associated peptides in patients with metastatic melanoma induced specific CD₈⁺ and CD₄⁺ T cell responses.¹⁷ However, tumor-infiltrating pDCs can also display tolerogenic properties contributing to tumor progression.⁹ ¹⁰ For example, it has been demonstrated that pDCs activate regulatory T cells (Tregs) via indoleamine 2,3-dioxygenase.¹⁸ The presence of tolerogenic pDCs may explain previous findings, indicating that a higher density of tumor-infiltrating pDCs is associated with poor prognosis in various cancer types such as head and neck, breast, and ovarian cancer.¹⁹ ²¹

So far, little is known about the potential role of pDCs in colon cancer and their impact on prognosis of patients. To gain novel insights into the clinical relevance of colon cancer-infiltrating pDCs, we determined the frequency of pDCs in primary tumor tissues and the association between pDC numbers and important clinicopathological characteristics of patients with colon cancer. In addition, we employed multiplex immunofluorescence stainings to explore the presence, localization, and phenotype of colon cancer-associated pDCs.

**Materials and Methods**

**Patients and study design**

This is a retrospective study including 149 patients with Union for International Cancer Control (UICC) stage I–IV colon cancer treated with primary resection at the University Hospital Carl Gustav Carus of Dresden between 2002 and 2013. Each case was classified according to the tumor, node, metastases staging system of the UICC. The clinicopathological characteristics of the patients are outlined in online supplemental table S1.

**Immunohistochemistry**

Formalin-fixed paraffin-embedded (FFPE) tissue blocks were cut into 3–5µm sections. Tissue preparation consisted of deparaffinization in xylene (2×8min, VWR International, Fontenay-sous-Bois, France) and rehydration by washes in graded ethanol (Berkel AHK, Ludwigshafen, Germany) to water (B. Braun, Melsungen, Germany). For antigen retrieval, the slides were boiled in citrate buffer (Zytomed Systems GmbH, Berlin, Germany) at pH 6.0 for 20min. To determine the presence and frequency of tumor-infiltrating pDCs, the tissue sections were stained overnight at 4°C with the polyclonal goat anti-BDCA-2 antibody (1:200, R&D Systems, Minneapolis, Minnesota, USA), followed by a 10min incubation with a mouse anti-goat antibody solution (Thermo Fisher Scientific, Rockford, Illinois, USA). Subsequently, labeling with dextran-coupled anti-mouse antibody (Dako, Glostrup, Denmark) was performed for all sections. pDCs were visualized by the alkaline phosphatase-based EnVision detection system according to the manufacturer’s instructions (Dako). Finally, all tissue sections were counterstained with Mayer’s hematoxylin (Merck, Darmstadt, Germany). For quantification, 80 randomly selected regions of interest (size 0.0835mm²) within every whole section were acquired (×400 magnification) using the Vectra 3 automated quantitative pathology imaging system (Akoya Biosciences, Menlo Park, California, USA). Positively stained pDCs were counted and the mean value was determined and converted into cell density.

**Immunofluorescence staining**

For additional experiments, we employed the Opal kit together with the Vectra 3 automated imaging system (both from Akoya Biosciences) to perform various multiplex immunofluorescence stainings. For the stainings conducted manually, tissues were deparaffinized and hydrated as described earlier. A microwave treatment in the AR6 or AR9 buffer (both from Akoya Biosciences) was applied in order to retrieve antigen retrieval. Subsequently, the Opal kit was used as described previously.²² Briefly, after a 10min blocking step, tissues were incubated with the primary antibody for 1h and then with a horseradish peroxidase-conjugated secondary antibody (Akoya Biosciences) for 10min. In the case of goat anti-human primary antibodies, a bridge step with a mouse anti-goat antibody (1:100, Thermo Fisher Scientific) preceded the application of the secondary antibody. Finally, one of the six TSA fluorophores available for Vectra 3 (Opal 520, 540, 570, 620, 650, and 690, all from Akoya Biosciences) was added to the tissue sections for 10min. Subsequent stripping of the primary together with secondary antibodies was performed by microwave treatment. All the steps mentioned earlier, starting with blocking and ending with the microwave treatment, were repeated for each of the primary antibodies.

For the stainings performed on the Ventana Ultra Instrument (Ventana Medical Systems, Arizona, USA), the steps employed were similar. Tissues were deparaffinized and antigen retrieval was performed in the cell conditioning 1 solution (Ventana Medical Systems). Incubation of the primary antibody followed for 32min at 36°C. Then, the appropriate secondary antibody (OmniMap anti-mouse, anti-rabbit or anti-goat antibody, ready-to-use, all from Ventana Medical Systems) was applied for 12min. Finally, one of the TSA fluorophores...
(Akoya Biosciences) was added to the tissue slides for 8 min. Stripping of the primary and secondary antibodies took place by heating the slides at 100°C in the cell conditioning 2 solution (Ventana Medical Systems). This sequence of steps (except deparaffinization and antigen retrieval) was repeated for each primary antibody.

Finally, for both the manual and automatic approach, all tissue slides were counterstained with spectral DAPI (Akoya Biosciences) and coverslipped with fluoromount medium (SouthernBiotech, Birmingham, Alabama, USA). The primary antibodies used for the various multiplex immunofluorescence stainings are summarized in online supplemental table S2.

Acquisition of the multispectral images was performed with the Vectra 3 automated imaging system (Akoya Biosciences). Spectral unmixing was done in the inForm software (Akoya Biosciences) using a library built from single stained tissue slides for each primary antibody-TSA fluorophore combination.

Quantification of the density of tertiary lymphoid structures (TLS) was conducted using the whole scans of all tissue sections stained with a seven-color multiplex immunofluorescence protocol. TLS were defined as aggregates of CD20+ cells surrounded by CD8+ and CD4+ lymphocytes that were associated with the tumor. The number of TLS was determined by a blinded observer and converted into frequency for each tissue section.

Analysis of microsatellite stability
To determine whether the 149 colon cancers are microsatellite stable (MSS) or microsatellite unstable (MSI), immunohistochemistry was performed on FFPE colon cancer tissue sections using an autostainer. The sections were deparaffinized and rehydrated, and heat-induced epitope retrieval was performed using the cell conditioning 1 solution (Ventana Medical Systems). Slides were incubated with primary antibodies for PMS2 (clone: EPR3947; diluted 1:1; Ventana Medical Systems) or MSH6 (clone: 44; diluted 1:1; Ventana Medical Systems). For visualization, the Roche OptiView DAB IHC Detection Kit (Ventana Medical Systems) was used and the samples were counterstained with hematoxylin. The expression of the mismatch repair (MMR) proteins (PMS2 and MSH6) was defined as absent (loss-MSI) when nuclear staining of tumor cells was not detectable despite positive staining in normal epithelial or stromal cells in at least one of the MMR proteins.

Analysis of public transcriptomic data
Publicly available data were downloaded from the NCBI Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) using the R software packages Biobase and affy. The following gene expression datasets, determined on the Affymetrix U133 Plus 2.0 Array, were used for this analysis: GSE33113, GSE31595, GSE38832, GSE39582, and GSE17536. Raw gene expression data was first processed using the frozen robust multi-array analysis (IRMA). Based on the intratumoral C-type lectin domain family 4 member C gene (CLEC4C) expression the patients were split into two groups and assessed by Kaplan-Meier curves and log-rank test.

Statistical analysis
Statistical analysis was performed using unpaired Student’s t-test for the evaluation of pDC density among the groups of patients with different clinicopathological characteristics. Kaplan-Meier curves were used to visualize differences in progression-free survival (PFS) and overall survival (OS). Significance was determined using the log-rank test. Using a Cox proportional hazards regression model, we explored the HR of the pDC infiltration in combination with clinicopathological characteristics of the patients. We assessed the spatial distribution of tumor-infiltrating immune cell subsets by calculating a cross-type cumulative distribution of the nearest neighbor distances for each pair of phenotypes using Ripley’s K function. Thereby, we determined the fraction of pDCs located close (≤25 µm) to CD8+ T cells or Tregs. All statistical analyses were performed using the software R (survival, survminer package). In all analyses, values of p≤0.05 were considered significant.

RESULTS
pDCs infiltrate human colon cancer
pDCs can essentially contribute to the induction and maintenance of antitumor immunity, resulting in tumor growth inhibition. However, they can also act as tolerogenic DCs by inhibiting tumor-directed immune responses, leading to tumor progression. In this context, it has been demonstrated that pDCs infiltrate a variety of human cancers and that a higher density is associated either with better7 or poor clinical outcome.19–21

To gain novel insights into the potential role of pDCs in colon cancer, we explored the presence and frequency of BDCA-2-expressing pDCs in tissue specimens from 149 patients with colon cancer with different clinicopathological characteristics (online supplemental table S1). BDCA-2 is a protein encoded by the CLEC4C gene that is characteristically expressed by pDCs and is involved in ligand internalization and antigen presentation.10 28 As depicted in figure 1A–C, pDCs were detectable in all colon cancer samples at varying frequencies (12.2±14.1 pDCs/mm2). They were preferentially located in the tumor stroma and often accumulated along the invasive tumor margin. These results indicate that pDCs are a component of the colon cancer-associated immune contexture and may contribute to the regulation of antitumor immune responses.

Higher frequency of infiltrating pDCs is associated with better prognosis for patients with colon cancer
Next, we investigated whether the density of pDCs in primary tumor tissues is associated with relevant clinicopathological characteristics of patients with
colon cancer. We found that a lower infiltration of pDCs is associated with locally more advanced tumors (figure 2A). Furthermore, tumors with lymph node or distant metastasis at the time of resection showed a lower density of infiltrating pDCs at the primary tumor site (figure 2B,C). A lower number of colon cancer-infiltrating pDCs correlated with an advanced UICC stage (figure 2D). Previously, it has been demonstrated that MSI-colorectal cancers are associated with a high density of activated CD8 T cells and a favorable prognosis of patients. Following these findings, we explored a potential link between the pDC frequency and the MSI/MSS status of our cohort comprising 23 MSI- and 126 MSS-colon cancers. However, the density of colon cancer-infiltrating pDCs did not differ between these two groups (online supplemental figure S1). In further experiments, we analyzed a potential correlation between the intratumoral pDC density and survival of patients. Interestingly, we found that an increased number of infiltrating pDCs was associated with an improved PFS and OS of patients with colon cancer (figure 3A,B). The 10-year PFS for patients with high pDC densities was 74% compared with 26% for patients with low pDC counts. Moreover, the 10-year OS for patients with colon cancer with high pDC frequencies was 82% compared with 49% for the cohort with low pDC values. To validate our findings, we took advantage of publicly available gene expression datasets of colorectal cancer specimens. Here, we evaluated the data from 1011 patients with colorectal cancer for the expression of CLEC4C in tissue samples. Each gene expression set was normalized using the fRMA method. The datasets were ranked for CLEC4C-expression and the top (208 patients) versus the bottom quartile (191 patients) was assessed for OS. Consistent with our observation, a higher expression of CLEC4C in colorectal cancer samples was significantly linked to an increased OS (figure 3C). Following these findings, we conducted a Cox multivariable regression analysis to assess the relevance of pDC density compared with clinicopathological characteristics. For a low pDC infiltration, we calculated a HR of 2.29 (95% CI 1.22 to 4.3), which was significantly associated with shorter PFS of patients with colon cancer and independent of patients’ gender, age at resection, and UICC stage (table 1).

Figure 2  Association between the frequency of plasmacytoid dendritic cells (pDCs) in tumor tissues and clinicopathological characteristics of patients with colon cancer. (A–D) Boxplots show the association between pDC infiltration and (A) local tumor progression state (pT stage), (B) lymph node metastases (pN stage), (C) distant metastases (M stage), and (D) combined Union for International Cancer Control (UICC) stage. Significant differences are indicated by asterisks (*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001).
Figure 3  Increased plasmacytoid dendritic cell (pDC) frequency is associated with better prognosis of patients with colon cancer. (A, B) Kaplan-Meier curves illustrate the association between the density of pDCs and (A) progression-free survival (PFS) and (B) overall survival (OS). (C) Kaplan-Meier curves demonstrate the correlation between CLEC4C expression in colorectal cancer tissues and OS of patients. The results were obtained from publicly available datasets of patients with colorectal cancer. Statistical comparison between groups of patients was conducted by using log-rank test.

Table 1  pDC infiltration is an independent prognostic factor for patients with colon cancer

| pDC infiltration                  | HR   | 95% CI  | Wald p value |
|-----------------------------------|------|---------|--------------|
| Low vs high                       | 2.29 | 1.22 to 4.3 | 0.01*        |
| UICC stage                        |      |         |              |
| II vs I                           | 2.06 | 0.56 to 7.54 | 0.27         |
| III vs I                          | 1.79 | 0.5 to 6.45  | 0.37         |
| IV vs I                           | 14.86| 4.05 to 54.57 | <0.0001**** |
| Age at resection                  | 0.99 | 0.97 to 1.01 | 0.23         |
| Sex                               |      |         |              |
| Female vs male                    | 0.71 | 0.4 to 1.26  | 0.24         |

Results of a multivariable Cox proportional hazards analysis of progression-free survival for 149 patients with colon cancer, including patients’ gender, age at resection, UICC stage, and pDC infiltration. Significance was assessed using the Wald p value and is indicated by bold font in the table (*p≤0.05, ****p≤0.0001). When testing for proportionality, none of the parameters violated the proportional hazard assumption (all p values >0.05).

**UICC, Union for International Cancer Control.**

...potential underlying mechanisms for the correlation between increased numbers of colon cancer-associated pDCs and better prognosis, we explored the spatial distribution of various T cell subsets in the neighborhood of pDCs in colon cancer tissues by using multiplex immunofluorescence staining (figure 4A–C). For this, we determined the spatial organization of pDCs to CD8+ T cells or FoxP3+CD4+ Tregs by calculating a cross-type cumulative distribution of the nearest neighbor distances G(r) for each pair of phenotypes (figure 4D). More explicitly, we analyzed which of the phenotypes (CD8+ or FoxP3+CD4+) is preferentially located in proximity (<25µm) to pDCs. Interestingly, we found that 49.5%±13.1% of all pDCs across the whole tissue sections of 47 colon cancer samples were located in the neighborhood of a CD8+ T cell (figure 4E). In contrast, only 14.2%±11.5% were located close to a Treg (figure 4E). Our data further suggests a clustered spatial arrangement, meaning that CD8+ cells and pDCs tend to locate nearby (figure 4D). Additionally, we evaluated the clinical significance of the location of pDCs close to CD8+ T cells by dividing the group of patients based on the fraction of neighboring cells and performed survival analysis. Thus, we observed a trend towards prolonged PFS for patients with a higher frequency of colon cancer-infiltrating pDCs located close to CD8+ T cells (figure 4F).

**Proportion of colon cancer-infiltrating pDCs displays an activated phenotype**

IFN regulatory factor 7 (IRF7) is a key transcriptional factor for the induction of type I IFN production and its nuclear expression is characteristic for activated pDCs, which are major producers of this cytokine. Activation of pDCs through TLR7 and TLR9 can trigger the
phosphorylation and nuclear translocation of IRF7, resulting in the induction of large amounts of type I IFN. To gain novel insights into the functional status of colon cancer-infiltrating pDCs and of CD8+ T cells, we conducted a multiparametric immunofluorescence staining of colon cancer samples using antibodies against pan-cytokeratin, BDCA-2, IRF7, CD8, and GrzB. We selected 10 tissue samples containing a high frequency of pDCs from patients with colon cancer with a good prognosis. As demonstrated in online supplemental figure S2A–C and figure 5A,B, activated pDCs characterized by a nuclear expression of IRF7 were present in all colon cancer tissue specimens at varying frequencies (mean: 27.6%, range: 1.8%–79.7%). As depicted in online supplemental figure S2A–C and figure 5A,B, we also found varying percentages of pDCs expressing the cytotoxic effector molecule GrzB in the analyzed tissues (mean: 12.1%, range: 2.5%–23.1%). When investigating the functional status of infiltrating CD8+ T cells, we detected a significant
proportion of colon cancer-infiltrating GrzB+ CD8+ T cells (mean: 30.0%, range: 9.0%–71.0%) as shown in online supplemental figure S2A–C and figure 5C. Tumor stroma regions with a colocalization of IRF7+ pDCs and GrzB+ CD8+ T cells were observed in all analyzed colon cancer tissues (online supplemental figure S2A–C). These results provide evidence that activated colon cancer-infiltrating pDCs may contribute to an efficient antitumor response by the production of soluble molecules such as type I IFN and GrzB as well as the stimulation of GrzB+ CD8+ T cells.

**pDCs are a component of colon cancer-associated TLS**

TLS are ectopic, organized lymphoid formations, which can occur in tumor tissues and are considered to play an important role in modulating adaptive antitumor immunity. Here, we identified colon cancer-associated TLS by multiplex immunofluorescence stainings based on the occurrence of CD4+ cells, CD8+ T cells, and CD20+ B cells and their organization in a lymph node-like structure. When investigating a potential correlation between the TLS density and clinical parameters of patients, we found that a higher TLS frequency is associated with improved PFS and OS of patients with colon cancer (online supplemental figure S3). Moreover, pDCs were detectable in colon cancer-associated TLS and were mainly located in the T cell zone (figure 6A–C). To explore the functional status of TLS-associated pDCs, we performed a multiparametric immunofluorescence staining of colon cancer samples using antibodies against BDCA-2, IRF7, CD3, CD4, and CD20. For this, tissue samples containing an appropriate number of TLS-associated pDCs from seven patients with colon cancer with a good prognosis were used. When analyzing 156 TLS across these tissues, we found that a relevant proportion (mean: 28.4%; range: 5.7%–55.1%) of TLS-associated pDCs shows a nuclear IRF7 expression and is preferentially located close to CD4+ T cells (online supplemental figure S4). These results demonstrate that pDCs are a cellular component of the TLS-associated T cell zone in colon cancer. Moreover, a proportion of these pDCs displays an activated phenotype, indicating that pDCs may participate in the induction and regulation of tumor-directed T cell responses.

**DISCUSSION**

Recent studies highlight the importance of the tumor immune contexture for the prognosis of patients with colorectal cancer. Thus, high densities of CD4+ Th1 cells and CD8+ T cells in the tumor center and the invasive margin were associated with improved survival of patients with colorectal cancer.

Recently, a multicenter study has been initiated to assess the prognostic value of tumor-infiltrating T cell numbers in patients with colon cancer. Patients with a so-called high Immunoscore, which is characterized by a high frequency of CD3+ and CD8+ T cells in the tumor center and the invasive margin, had the longest survival and the lowest risk of recurrence. These results suggest that the Immunoscore may represent a reliable estimate of the risk of disease recurrence and support its implementation in the classification of colon cancer. In addition to T cells, the clinical impact of colorectal cancer-infiltrating macrophages has been explored. A pooled analysis of various studies has shown that a high density of colorectal cancer-infiltrating macrophages is associated with favorable OS.

Previous studies revealed that DCs, as key regulators of innate and adaptive antitumor immunity, are a component of the immune architecture in colorectal cancer and may influence the clinical outcome of patients. Thus, it has been reported that S-100+ DCs are detectable in almost all colorectal specimens and are mainly located in the tumor stroma. Increased densities of tumor epithelium-infiltrating S-100+ DCs were associated with higher numbers of intraepithelial CD4+ and CD8+ T cells. When investigating the clinical impact of colorectal cancer-infiltrating DCs, it has been demonstrated that a higher frequency of S-100+ DCs is correlated with prolonged survival of patients. However, other studies did not find a statistically significant association
between colorectal cancer-infiltrating S-100+ DCs and improved prognosis.\textsuperscript{40,41} It has also been reported that DCs expressing the maturation marker CD83 are detectable in colorectal cancer and are located predominantly in the invasive margin of the cancer stroma, often in clusters with lymphocytes.\textsuperscript{45,44} In addition, a lower number of CD83+ DCs was found in locally advanced tumors.\textsuperscript{43} Whereas all these findings rely on the detection of general marker molecules that are not selectively expressed by DCs, studies investigating the frequency and clinical impact of distinct human DC subsets in colon cancer tissues are rather limited.

In the present study, we explored the frequency of colon cancer-infiltrating BDCA-2\textsuperscript{+} (CLEC4C) pDCs and their correlation with clinicopathological characteristics of patients. We found that pDCs are detectable in all primary tumor tissues, indicating that pDCs represent an immune contexture component of colon cancer. Notably, a higher density of infiltrating pDCs was linked to lower tumor stages and to improved PFS and OS of patients with colon cancer. This was further substantiated by publicly available gene expression datasets of a large cohort of colorectal cancer specimens, demonstrating that the expression of CLEC4C was correlated with prolonged OS of patients. These findings are in line with a recent study, indicating that a higher z-score for a pDC subset-specific gene signature is linked to an increased probability of disease-free survival for patients with luminal breast cancer.\textsuperscript{7} Similar findings have been reported for blood-circulating pDCs in breast cancer, where higher levels of pDCs represented a positive prognostic indicator.\textsuperscript{45} In contrast, previous studies revealed that a higher density of pDCs is associated with poor clinical outcome for patients with head and neck, breast, hepatocellular, and ovarian cancer.\textsuperscript{19,21,46}

When exploring the underlying mechanisms for this correlation, it has been shown that head and neck cancer can efficiently suppress the ability of infiltrating pDCs to produce IFN-\(\alpha\) upon activation with a TLR9 agonist, which may be based on the tumor-induced downregulation of TLR9 expression.\textsuperscript{19} This finding was further substantiated by studies demonstrating a reduced capacity of ovarian cancer- and breast cancer-associated pDCs to produce IFN-\(\alpha\) upon stimulation.\textsuperscript{21,47} Breast cancer-derived transforming growth factor \(\beta\) and tumor necrosis factor \(\alpha\) were shown to impair the IFN-\(\alpha\) production of pDCs by blocking IRF7 expression and nuclear translocation.\textsuperscript{48} In addition, it has been reported that breast cancer-associated pDCs efficiently promote the expansion of Tregs.\textsuperscript{47}

To gain novel insights into the role of colon cancer-infiltrating pDCs that may explain the correlation between a higher pDC frequency and better survival, we explored a potential colocalization of pDCs with CD8\textsuperscript{+} T cells. Activated CD8\textsuperscript{+} T cells are characterized by the production of pro-inflammatory cytokines and an extraordinary cytotoxic potential. Due to these functional properties, CD8\textsuperscript{+} T cells play an essential role in antitumor immunity. We demonstrated that a higher number of pDCs is located close to CD8\textsuperscript{+} T cells in tumor stroma. When further analyzing the phenotype of colon cancer-infiltrating pDCs, we found a relevant proportion of activated pDCs that were characterized by the nuclear expression of IRF7, representing a master transcription factor for the induction of type I IFN production.\textsuperscript{9,10,32} A lower percentage of pDCs expressing the cytotoxic effector molecule GrzB was also detected. Furthermore, we observed a significant proportion of colon cancer-infiltrating GrzB\textsuperscript{+} CD8\textsuperscript{+} T cells. The colocalization of IRF7\textsuperscript{+} pDCs and GrzB\textsuperscript{+} CD8\textsuperscript{+} T cells in various tumor regions provides evidence that activated pDCs may contribute to the stimulation of tumor-reactive CD8\textsuperscript{+} cytotoxic T cells. These observations indicate that the tumor microenvironment plays an important role in shaping the functional properties (tolerogenic vs activated) of infiltrating pDCs that may influence the regulation of tumor growth and the prognosis of patients.

Tumor-associated TLS are characterized by features of lymph nodes including a T-cell zone with DCs and a germinal center with follicular DCs and proliferating B cells, indicating that these lymphoid structures may play an important role in modulating adaptive antitumor immunity.\textsuperscript{54,49} Previous studies have indicated that a higher frequency of TLS is associated with better prognosis of patients with cancer.\textsuperscript{13} In addition, accumulating evidence suggests that TLS essentially contribute to the therapeutic efficacy of CPI in patients with tumor.\textsuperscript{50} Thus, it has been demonstrated that higher numbers of tumor-associated TLS are detectable in treatment responders and are correlated with increased survival of patients with cancer receiving CPI therapy.\textsuperscript{51–53} When focusing on the localization and phenotype of TLS-associated DCs in patient-derived tumor tissues, a high frequency of TLS-associated DCs expressing the maturation marker lysosomal-associated membrane protein has been linked to a strong infiltration of T cells in non-small cell lung cancer.\textsuperscript{54} The density of mature DC was also associated with expression of genes related to T-cell activation, Th1 phenotype, and cytotoxic orientation. Moreover, a high number of TLS-associated DCs correlated with long-term survival of patients. Here, we observed that pDCs are present in colon cancer-associated TLS and are preferentially located close to CD4\textsuperscript{+} T cells within the T-cell zone. When investigating the potential role of TLS-associated pDCs, we found that a significant proportion pDCs shows a nuclear IRF7 expression, which is characteristic for an activated phenotype. These findings indicate that TLS-associated pDCs may participate in the induction and regulation of CD4\textsuperscript{+} T cell responses. CD4\textsuperscript{+} effector T cells can essentially contribute to antitumor immunity by enhancing the capacity of DCs to induce CD8\textsuperscript{+} T cell responses and by providing help for the expansion of CD8\textsuperscript{+} T cells directly.\textsuperscript{55} In addition, they can kill tumor cells and promote the differentiation of B cells into antibody-producing plasma cells.

In summary, we found that pDCs are present in all primary tumor tissues and that a higher density of infiltrating pDCs is associated with lower tumor stages and
improved PFS and OS of patients with colon cancer. Moreover, a lower pDC density was significantly and independently linked to worse prognosis, indicating that infiltrating pDCs may represent a novel prognostic factor for patients with colon cancer. In addition, we demonstrated that a proportion of colon cancer-associated pDCs displays a nuclear expression of IRF7, which is characteristic for an activated phenotype. In various tumor stroma regions, IRF7+ pDCs were located in the neighborhood of GrzB+ CD8+ T cells. Furthermore, our studies revealed that a higher number of colon cancer-associated TLS is linked to better prognosis and that pDCs are a novel component of the T cell zone of TLS. A proportion of the TLS-associated pDCs showed a nuclear IRF7 expression and was preferentially located close to CD4+ T cells. The colocalization of pDCs and T cells in tumor stroma and TLS may lead to the induction and maintenance of efficient T cell-mediated antitumor responses and may contribute to the association between high pDC frequencies and better prognosis for patients with colon cancer.

Author affiliations
1Institute of Immunology, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany
2Institute of Pathology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
3National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany
4German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany
5University Cancer Center, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
6Department of Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
7Center for Regenerative Therapies Dresden (CRTD), TU Dresden, Dresden, Germany
8Department of Thoracic Oncology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
9Institute of Radiopharmaceutical Cancer Research, Helmholtz Center Dresden-Rossendorf (HZDR), Dresden, Germany
10Tumor and normal tissue bank of the University Cancer Center, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany

Acknowledgements We thank Bärbel Löbel and Susanne Doms for excellent technical assistance.

Contributors Conception and design: MK, IP, GB, MS. Acquisition of data: MK, IP, US, GB, MS. Analysis and interpretation of data: MK, IP, US, AR, AMS, GB, MS. Writing, review, and/or revision of the manuscript: MK, IP, US, AR, AMS, GB, MS. Study supervision: MS.

Funding This study was supported by grants from the Federal Ministry of Education and Research (01Z1912C) and the Faculty of Medicine, TU Dresden to R. Wehner.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This study was approved by the institutional review board of the Faculty of Medicine of the TU Dresden. Patients gave their written informed consent.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Adrian M Seifert http://orcid.org/0000-0002-5329-3164
Marc Schmitz http://orcid.org/0000-0003-3417-6736

REFERENCES
1 Fridman WH, Zitvogel L, Sauvé-Fridman C, et al. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 2017;14:717–34.
2 Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018;24:541–50.
3 Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity 2020;52:55–81.
4 Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 2020;20:662–80.
5 Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–71.
6 Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 2015;15:133–50.
7 Michea P, Noël F, Zakine E, et al. Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. Nat Immunol 2018;19:885–97.
8 Blättcher JP, Bonavita E, Chakravarty P, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 2018;172:1022–37.
9 Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 2015;15:471–85.
10 Wólczyk SK, Cueto FJ, Mujal AM, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 2020;20:27–4.
11 Saliou M, Cella M, Vermi W, et al. Plasmacytoid dendritic cells prime IFN-gamma-securing melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003;33:1052–62.
12 Hanabuchi S, Watanabe N, Wang Y-H, et al. Human plasmacytoid pre-dendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood 2006;107:3617–23.
13 Stary G, Bangert C, Tauber M, et al. Tumoralidic activity of TL7R9–activated inflammatory dendritic cells. J Exp Med 2007;204:1441–51.
14 Drobys B, Holcmann M, Amberg N, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012;122:575–85.
15 Liu C, Lou Y, Lizée G, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008;118:1165–75.
16 Le Mercier I, Poujol D, Sanlaville A, et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TL7R ligand treatment. Cancer Res 2013;73:4629–40.
17 Teil J, Aarnetzen EHJG, Baba T, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013;73:1063–75.
18 Sharma MD, Baban B, Chandler P, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007;117:2570–82.
19 Hartmann E, Wollenberg B, Rothenfusser S, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003;63:6478–87.
20 Treilleux L, Blay J-Y, Bendriss-Vermare N, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clín Cancer Res 2004;10:7466–74.
21 Labidi-Galy SI, Sisirak V, Meeus P, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011;71:5423–34.
et al. Neoadjuvant 30 39 38 27 35 34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1

Feng Z, Bethmann D, Kappler M, Am J Pathol content of activated cytotoxic lymphocytes identify colon cancer

Guidoboni M, Gafà R, Viel A, Lancet Pagès F gene expression profile predicts recurrence and death in patients

Smith JJ, Deane NG, W J Clin Oncol outcome.

Pagès F, J Cancer Res of immune cells within human colorectal tumors predict clinical

van Marisa L, de Reyniès A, Duval A, PLoS Med of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

of T cells predict outcome in patients with early-

outcome. Nature 2016;27:1579–86.

and ductal carcinoma.

B, inducible T cells are a poor prognostic factor for prostate cancer following curative resection. Cancer Immunol Immunother 2019:68:1223–33.

et al. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 2012;72:5188–97.

Sisirak V, Vey N, Goutagny N, et al. Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells. Int J Cancer 2013;133:771–8.

Dieu-Nosjean M-C, Giraldo NA, Kaplon H, et al. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol Rev 2016;271:260–75.

Plescia I, Tunger A, Müller L, et al. Characteristics of tumor-infiltrating lymphocytes prior to and during immune checkpoint inhibitor therapy. Front Immunol 2020;11:1–8.

Petitprez F, de Reyniès A, Keung EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 2020;577:556–60.

Helminka RA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 2020;577:549–55.

Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 2020;577:961–5.

Goc J, Fridman W-H, Sautès-Fridman C, et al. Characteristics of tertiary lymphoid structures in primary cancers. Oncoimmunology 2013;2:e268836.

Sautès-Fridman C, Petitprez F, Calderaro J, et al. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 2019;19:307–25.

Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1860–4.

Pagès F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009;27:5944–51.

Pagès F, Mlecnik B, Marlot F, et al. International validation of the consensus immunoscope for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018;391:2128–39.

Li J, Li L, Li Y, et al. Tumor-Associated macrophage infiltration and prognosis in colorectal cancer: systematic review and meta-analysis. Int J Colorectal Dis 2020;35:1203–10.

Ambe K, Mori M, Enjoji M, S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 1989;63:496–503.